Certified Asthma Educator (AE‑C) Practice Test

The combination of medium-dose inhaled corticosteroids (ICS) and leukotriene receptor antagonists (LTRA) is a recognized approach for managing moderate persistent asthma in children aged 5-11. This treatment strategy addresses the underlying inflammation associated with asthma, as ICS plays a critical role in controlling airway inflammation. At the same time, LTRAs help to alleviate bronchoconstriction and improve overall asthma control.

Utilizing medium-dose ICS is effective because it balances the need for sufficient anti-inflammatory action without the potential side effects associated with higher doses. The LTRA adds an additional mechanism of action by targeting leukotrienes, which are inflammatory mediators that can exacerbate asthma symptoms. This combination can lead to a better control of asthma symptoms while minimizing the risk of side effects.

The other options may not be suitable for this age group or do not represent first-line therapy for moderate persistent asthma in children. For instance, the low-dose ICS and LABA combination is typically reserved for more severe cases, and high-dose ICS may increase the risk of adverse effects without sufficiently adding to therapeutic benefit for young children. The use of theophylline, especially in combination with medium-dose ICS, is less common nowadays due to its side effect profile and the availability of